RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system

Summary

Local drug delivery has become an important treatment modality for the prevention of thrombotic events following coronary angioplasty. In this study, we investigate the ability of liposomes bearing surface conjugated linear Arg-Gly-Asp (RGD) peptide (GSSSGRGD SPA) moieties to target and bind activated platelets, and the effect of such RGD-modified liposomes on platelet activation and aggregation. The binding of RGD-liposomes to human platelets was assessed by fluorescence microscopy,phase contrast microscopy and flow cytometry. The effect of RGDmodified liposomes on platelet activation and aggregation was investigated in vitro, with and without platelet agonists. RGD-liposomes were found to bind activated platelets at levels significantly greater than the control RGE-liposomes.The RGD-liposomes did not exhibit any statistically significant effect on platelet activation or aggregation.The results demonstrate the ability of the RGD-modified liposomes to target and bind activated platelets without causing significant platelet aggregation and suggests a feasible way for the development of a platelet-targeted anti-thrombogenic drug delivery system. Furthermore, the approach can be extended to the development of liposomes for other vascular targets, for application in drug delivery or gene therapy.

Keywords

Liposomes - RGD-modification - platelet-targeted - drug delivery

• References

• 1 Fishbein I, Waltenberger J, Banai S. et al Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 2000; 20: 667-76.
• 2 Kandarpa K, Nakatsuka S, Bravo SM. et al Mural delivery of iloprost with use of hydrogel-coated balloon catheters suppresses local platelet aggregation. J Vasc Interv Radiol 1997; 8: 997-1004.
• 3 Nugent HM, Edelman ER. Local drug delivery and tissue engineering regulate vascular injury. Curr Pharm Des 1997; 3: 529-44.
• 4 Mauro L, Borovicka M, Kline S. Introduction to coronary artery stents and their pharmacotherapeutic management. Ann Pharmacother 1997; 31: 1490-8.
• 5 Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28: 1643-51.
• 6 Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 1996; 78: 35-40.
• 7 Jang Y, Lincoff A, Plow EF. et al Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
• 8 Barron M, Lake R, Buda A. et al Intimal hyperplasia after balloon injury is attenuated by blocking selectins. Circulation 1997; 96: 3587-92.
• 9 D'Souza SE, Ginsberg MH, Natsueda GR. et al A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991; 350: 66-68.
• 10 Cierniewski CS, Byzova T, Papierak M. et al Peptide ligands can bind to distinct sites in Integrin aIIbß 3 and elicit different functional responses. J Biol Chem 1999; 274: 16923-32.
• 11 Deckmyn H, Ulrichts H, Van de Walle G. et al Platelet antigens and their function. Vox Sanguinis 2004; 87: S105-S111.
• 12 Pytela R, Piersbacher MD, Ginsberg MH. et al Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-62.
• 13 Lam SC-T, Plow EF, Smith MA. et al Evidence that arginyl-glycyl-aspartate peptides share a common binding site on platelets. J Biol Chem 1987; 262: 947-50.
• 14 Gyongyossy-Issa I M, Muller W, Devine DV. The covalent coupling of Arg-Gly-Asp-containing peptides to liposomes: purification and biochemical function of the lipopeptide. Arch Biochem Biophys 1998; 353: 101-8.
• 15 Nishiya T, Sloan S. Interaction of RGD liposomes with platelets. Biochem Biophys Res Commun 1996; 224: 242-5.
• 16 Berndt P, Fields GB, Tirrell M. Synthetic lipidation of peptides and amino acids: monolayer structure and properties. J Am Chem Soc 1995; 117: 9515-22.
• 17 Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int Journal Peptide Protein Res 1990; 35: 161-214.
• 18 Plow E, Pierschbacher M, Ruoslahti E. et al Arginyl- glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 1987; 70: 110-15.
• 19 D'Souza SE, Haas TA, Piotrowicz RS. et al Ligand and cation binding are dual functions of a discrete segment of the integrin b3 subunit: cation displacement is involved in ligand binding. Cell 1994; 79: 659-67.
• 20 Lestini BJ, Sagnella SM, XY Z. et al Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Control Rel 2002; 78: 235-47.
• 21 Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996; 87: 4925-36.
• 22 Schmitz G, Rothe G, Ruf A. et al European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-96.
• 23 Craig WS, Cheng S, Mullen DG. et al Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers (Peptide Science) 1995; 37: 157-75.
• 24 Beer JH, Springer KT, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 1992; 79: 117-28.
• 25 Male R, Vannier WE, Baldeschwieler JD. Phagocytosis of liposomes by human platelets. Proc Natl Acad Sci U S A 1992; 89: 9191-5.